EMA begins reviewing Sanofi-GSK COVID-19 vaccine

Wednesday, 30. March 2022 17:37

The European Medicines Agency announced on Wednesday it has started the review of the COVID-19 vaccine jointly developed by French healthcare company Sanofi and its British partner GlaxoSmithKline.

The vaccine known under the name Vidprevtyn, has been determined to be 100% effective against severe COVID-19 and hospitalization, according to the results of the late-stage trials conducted by the two companies.

While the European Union already agreed to buy 300 million doses of the two-shot vaccine for €324 million, GSK also confirmed the companies would request the authorization of the jab in the United States in the upcoming weeks.

Related Links: Sanofi S.A.GlaxoSmithKline PLC
Baha Breaking News (BBN) / ND